Ovarian Cancer Patient Tool
Treatment Options From 5 Experts for Advanced Ovarian Cancer: An Online Tool for Patients

Released: May 21, 2020

Expiration: May 20, 2021

References

American Cancer Society. Treatment of invasive epithelial ovarian cancers, by stage. Available at: https://www.cancer.org/cancer/ovarian-cancer/treating/by-stage.html. Accessed April 20, 2020.

American Cancer Society. What is ovarian cancer? Available at: https://www.cancer.org/cancer/ovarian-cancer/about/what-is-ovarian-cancer.html. Accessed April 20, 2020.

Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer. 2014;24(9 suppl 3):S55-S60.

Bevacizumab [package insert]. South San Francisco, CA: Genentech, Inc.; 2019.

Boulanger J, Boursiquot JN, Cournoyer G, et al. Management of hypersensitivity to platinum- and taxane-based chemotherapy: CEPO review and clinical recommendations. Curr Oncol. 2014;21:e630-e641.

Cisplatin [package insert]. Paramus, NJ: HQ Specialty Pharma; 2019.

Colombo N, Sessa C, du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30:672-705.

da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, et al. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo). 2018;73(suppl 1):e450s.

Evans T, Matulonis U. PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol. 2017;9:253-267.

Fotopoulou C. Limitations to the use of carboplatin-based therapy in advanced ovarian cancer. EJC Suppl. 2014;12:13-16.

Gourley C, Farley J, Provencher DM, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer. 2014;24(9 suppl 3):S9-S13.

Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(suppl 4):iv45-iv54.

Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in Southwest Oncology Group Clinical Trials. J Clin Oncol. 2016;34:3014-3022.

Kurman RJ, Carcangiu ML, Herrington CS, et al, editors. WHO Classification of Tumours of Female Reproductive Organs. Fourth edition. Lyon, France: International Agency for Research on Cancer; 2014.

LaFargue CJ, Dal Molin GZ, Sood AK, et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20:e15-e28.

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409-413.

Ledermann JA, Luvero D, Shafer A, et al. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 suppl 3):S14-S19.

Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280-304.

Li M, Li H, Liu F, et al. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy. J Ovarian Res. 2017;10:9.

MD Anderson Cancer Center. Epithelial ovarian cancer. Approved December 18, 2018. Available at: https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/cancer-treatment/ca-treatment-ovarian-web-algorithm.pdf. Accessed April 20, 2020.

MedlinePlus. Endometriosis. Available at: https://medlineplus.gov/endometriosis.html. Accessed April 20, 2020.

Molassiotis A, Cheng HL, Leung KT, et al. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. Brain Behav. 2019;9:e01312.

National Cancer Institute. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®)–patient version. Updated May 22, 2019. Available at: https://www.cancer.gov/types/ovarian/patient/ovarian-epithelial-treatment-pdq. Accessed April 20, 2020.

National Cancer Institute. Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment (PDQ®)–health professional version. Updated June 5, 2019. Available at: cancer.gov/types/ovarian/hp/ovarian-epithelial-treatment-pdq. Accessed April 20, 2020.

National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: ovarian cancer. Available at: https://seer.cancer.gov/statfacts/html/ovary.html. Accessed April 20, 2020.

Niraparib [package insert]. Waltham, MA: Tesaro, Inc.; 2019.

Olaparib capsules [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2018.

Olaparib tablets [package insert]. Gaithersburg, MD: AstraZeneca Pharmaceuticals LP; 2019.

Pembrolizumab [package insert]. North Wales, PA: Merck Sharp & Dohme Corp; 2019.

Rucaparib [package insert]. Boulder, CO: Clovis Oncology, Inc; 2018.

Santaballa A, Barretina P, Casado A, et al. SEOM clinical guideline in ovarian cancer (2016). Clin Transl Oncol. 2016;18:1206-1212.

Starobova H, Vetter I. Pathophysiology of chemotherapy-induced peripheral neuropathy. Front Mol Neurosci. 2017;10:174.

Stone RL, Sood AK, Coleman RL. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol. 2010;11:465-475.

US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Accessed April 20, 2020.

Disclaimer: Access to and use of this Interactive Decision Support Tool titled, “Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Ovarian Cancer,” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate patients on potential treatments for stage II-IV epithelial ovarian cancer where systemic therapy is indicated. The information provided is based on the expert guidance of Robert L. Coleman, MD; Thomas J. Herzog, MD; Ursula Matulonis, MD; Bradley J. Monk, MD, FACS, FACOG; and Kathleen Moore, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the US Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Decision Support Tool: Treatment Selection for Patients With Advanced Ovarian Cancer” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2020 Clinical Care Options, LLC. All rights reserved.

Program Content